BioSpace News Archive

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 14,200 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros.

Basilea Pharmaceutica Ltd. announced that its license partner Asahi Kasei Pharma, has received the marketing authorization from the Ministry of Health, Labour and Welfare in Japan for Cresemba® for the treatment of adult patients with aspergillosis, mucormycosis, and cryptococcosis.

Hansa Biopharma announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting on June 30, 2022 and has the following composition.

Outlook Therapeutics, Inc. today announced that it has entered into securities purchase agreements with existing institutional and accredited investors for the purchase and sale of 28,460,831 shares of common stock at a purchase price of $0.8784 per share in a registered direct offering.

atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers.

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 11 , 2023.

180 Life Sciences Corp. today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused U.S. institutional investor of 1,714,286 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of common stock.

Immutep Limited today announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 protein, eftilagimod alpha (“efti”), in conjunction with standard-of-care chemotherapy for the treatment of metastatic breast cancer (MBC).

MediWound Ltd. today announced that its partner, Kaken Pharmaceutical Co., Ltd. has gained marketing approval of NexoBrid® in Japan.